Nishimura & Asahi Advised MBK Partners On Acquisition Of Alinamin Pharmaceuticals
Japanese law firm Nishimura & Asahi has represented private equity group MBK Partners in its acquisition of drugmaker
Nishimura & Asahi Advised MBK Partners On Acquisition Of Alinamin Pharmaceuticals
Japanese law firm Nishimura & Asahi has represented private equity group MBK Partners in its acquisition of drugmaker Alinamin Pharmaceuticals for 350 billion yen ($2.17 billion) from private equity giant Blackstone.
Blackstone was advised by its longstanding firm, Simpson Thacher & Bartlett.
Following the sale, Blackstone will reinvest in a minority stake in Alinamin.
Blackstone had originally acquired Alinamin in 2020 from Takeda Pharmaceutical, marking what was then the largest healthcare transaction in Japan.
The Nishimura & Asahi team on the deal was led by M&A Partners Hiroshi Uchima, Junya Kokaji, and Hudson Hamilton, with support from Finance Partner Toshiyuki Nonaka, Life Sciences Regulatory and Compliance Partner Alisa Inuzuka, and Associate Kaori Furuya.
Simpson Thacher’s team was led by Transactions Partner Anthony King, with Associates Sonya Ho and Paul Kim. The team also included Partners Étienne Renaudeau (Antitrust), Makiko Harunari (Banking), Steven Klar (Funds), Gregory Grogan (ECEB), and Senior Tax Counsel Meredith Jones.